Showing posts with label ViiV Healthcare. Show all posts
Showing posts with label ViiV Healthcare. Show all posts
Thursday, June 5, 2025

ViiV's Positive Perspectives Research Provides Insights to Patient-Provider Relationships

›
By:  Ranier Simons , ADAP Blog Guest Contributor The doctor-patient relationship is the cornerstone of healthcare. Patients cannot fully ben...
Thursday, July 18, 2024

HIV LONG-ACTING INJECTABLES: Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis

›
By:  Brandon M. Macsata , CEO, ADAP Advocacy; Jen Laws , President & CEO, Community Access National Network (CANN); Marcus J. Hopkins , ...
Thursday, June 13, 2024

What are 'Major Statements' for Direct-to-Consumer Pharmaceutical Advertisements

›
By:  Ranier Simons , ADAP Blog Guest Contributor In the United States, it is common to see advertisements for drugs. Ads appear in print mag...
Thursday, March 14, 2024

CROI 2024 Highlights: Conference on Retroviruses and Opportunistic Infections

›
By:  Ranier Simons , ADAP Blog Guest Contributor The fight against HIV and other viruses like HCV and SARS-CoV-2 is a worldwide team effort....
Thursday, February 29, 2024

Evidence Suggests Long-Acting Injectables Game Changer for Adherence

›
By:  Ranier Simons , ADAP Blog Guest Contributor Adherence to medication is one of the most important tenets of antiretroviral therapy (ART)...
Thursday, July 20, 2023

The State of Long-Acting Injectable Medicaid Coverage

›
By:  Marcus J. Hopkins , ADAP Blog Guest Contributor, and Founder & Executive Director of the Appalachian Learning Initiative (APPLI) A ...
1 comment:
Thursday, June 9, 2022

Ramifications of Pharmaceutical Supply Chain Challenges

›
By:  Ranier Simons , ADAP Blog Guest Contributor The COVID-19 pandemic has globally brought awareness to many aspects of daily life that pre...
Thursday, February 17, 2022

FDA Extends Cabenuva Approval to Every Two Months

›
By:  Ranier Simons , ADAP Blog Guest Contributor The primary weapons in the fight against HIV are anti-retroviral drugs, commonly referred t...
Thursday, April 8, 2021

Cabenuva is a Shot 💉 of Hope for People Living with HIV/AIDS

›
By: Brandon M. Macsata, CEO, ADAP Advocacy Association On January 21, 2021, a shot of hope was provided by the U.S. Food & Drug Administ...